Nevertheless, there seems to be conflicting data in the extant literature regarding both the degree of neuroprotection and the behavioural effects of dual mGluR2/3 treatment in vivo in animal models of PD, which may in part be related to the differing routes of administration employed in each study. The gene discussed is GRM2; the disease is Parkinson disease.